neovascular age-related macular degeneration
Conditions
Interventions
Group 2:Group 2 were treated with a T&E regimen and received intravitreal injection of Aflibercept (2 mg)
Group 1:Group 1 were treated with a T&E regimen and received intravitreal injection of Conbercept (0.5 mg)
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Inclusion criteria
Inclusion criteria: The eligibility criteria for the study included patient's age=50 years; nAMD is confirmed through mydriatic slit lamp examination, OCT, OCTA, FFA and ICGA; No previous treatment related to nAMD (intravitreal drug injection, PDT, etc; Patients who can complete treatment follow-up for at least 12 months.
Exclusion criteria
Exclusion criteria: Patients will be excluded if they meet the following criteria. Combined with other fundus diseases, such as retinal detachment, pathological myopia, proliferative diabetic retinopathy, glaucoma, retinal vascular obstructive disease, macular membrane, macular hole, etc;Internal eye surgery or fundus laser treatment has been performed in the past, or there is a history of severe ocular trauma;Severe turbidity in the refractive medium affects the observation of fundus;Patients who failed to receive regular follow-up coordination treatment and had a follow-up period of less than 12 months and lost to follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Best-Corrected Visual Acuity(BCVA); | — |
Secondary
| Measure | Time frame |
|---|---|
| Central Retinal Thickness(CRT);injection frequency;Intraocular Pressure; | — |
Countries
China
Contacts
Public ContactHui peng
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed